Skip to main content

Table 3 CT features of patients with COVID-19

From: Predictors of fatality including radiographic findings in adults with COVID-19

 

Week 1 (≤ 7d) after symptom onset

Week 2 (> 7d, ≤ 14d)

Week 3(>14d, ≤ 21d)

Week 4(>21d, ≤ 28d)

 

Survivor (n = 21)

Non-Survivor (n = 11)

Survivor(n = 22)

Survivor(n = 25)

Survivor(n = 23)

Severity score of each lobe

 Right upper lobe

1 (0–1.5)

3 (2–4)***

2 (1–2)

1 (0.5–2)

1 (0–2)

 Right middle lobe

0 (0–1)

2 (1–2)

1 (0–1)

0 (0–1)

0 (0–1)

 Right lower lobe

1 (1–3)

3 (3–4)

2.5 (1–3)

1 (1–2.5)

1 (1–2)

 Left upper lobe

1 (0–1.5)

3 (1–4)

1.5 (0–3)

1 (0–2)

1 (0–2)

 Left lower lobe

1 (0–2.5)

4 (3–5)***

2 (1–3.25)

1 (1–2.5)

1 (0–2)

Total severity score

4 (2–9.5)

15 (9–19)****

8 (4–12.25)

5 (3–10)

4 (2–9)

  < 15

20 (95.24%)

4 (36.36%)***

19 (86.36%)

23 (92%)

22 (95.65%)

  ≥ 15

1 (4.76%)

7 (63.64%)

3 (13.64%)

2 (8%)

1 (4.35%)

Number of involved lobes

3 (1.5–5)

5 (4–5)**

4.5 (3–5)

4 (3–5)

3 (2–5)

  < 5

14 (66.67%)

2 (18.18%)*

11 (50%)

15 (60%)

14 (60.87%)

  = 5

7 (33.33%)

9 (81.82%)

11 (50%)

10 (40%)

9 (39.13%)

Lung involvement

 No involvement

2 (9.52%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 Unilateral

4 (19.05%)

0 (0%)

0 (0%)

4 (16%)

3 (13.04%)

 Bilateral

15 (71.43%)

11 (100%)

22 (100%)

21 (84%)

20 (86.96%)

Patterns of opacification

 Ground glass opacity

20 (95.24%)

10 (90.91%)

21 (95.45%)

18 (72%)

20 (86.96%)

 Crazy-paving pattern

2 (9.52%)

5 (45.45%)*

5 (22.72%)

3 (12%)

4 (17.39%)

 Consolidation

9 (42.86%)

9 (81.82%)

15 (68.19%)

14 (56%)

1 (4.35%)**

 Reticulation

0 (0%)

2 (18.18%)

3 (13.64%)

9 (36%)**

15 (65.22%)****

 Pleural effusion

1 (4.76%)

3 (27.27%)

1 (4.55%)

0 (0%)

0 (0%)

Distribution of opacification

 No lesion

2 (9.52%)

0 (0%)

0 (0%)

0 (0%)

0 (0%)

 Peripheral

10 (47.62%)

8 (72.73%)

13 (59.09%)

18 (72%)

17 (73.91%)

 Random

6 (28.57%)

0 (0%)

2 (9.09%)

0 (0%)**

0 (0%)**

 Diffuse

3 (14.29%)

3 (21.27%)

7 (31.82%)

7 (28%)

6 (26.09%)

Time between symptom onset and CT scan

4 (2.5–5)

5 (2–6)

11.5 (9–13.25)

18 (16–20)

26 (24–28)

  1. Data are median (IQR), or n (%). χ2 test, Mann-Whitney U test or Fisher’s exact test were used to compare the data of survivors in week 1 with those of non-survivors, and with the data of survivors in week 2, 3, 4, respectively. One-way ANOVA with Bonferroni’s multiple comparison test was used for comparison of total severity scores of the 4 weeks in survivors. ****, p < 0.0001; ***, p < 0.001; **, p < 0.01; *, p < 0.05